Rhythm Pharmaceuticals: PWS early data fuels stock optimism – aHO decision on March 20, 2026 remains the main driver
Reading Time: 3 minutes
Commercially already on the market: IMCIVREE (Setmelanotid) reduces the "all-or-nothing" risk of classic biotechs PWS momentum with caution: Preliminary open-phase 2 data show "meaningful" improvements in hyperphagia and some BMI reductions PWS update from December 11, 2025 On December 11, 2025, Rhythm presented preliminary data from an exploratory phase-2 study on Prader-Willi syndrome (PWS) and simultaneously indicated the intention to transition the approach into a regulatory program. In an indication where hyperphagia – a pathological,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
